Literature DB >> 15880750

Radiotherapy alone or combined with surgery for salivary gland carcinoma.

William M Mendenhall1, Christopher G Morris, Robert J Amdur, John W Werning, Douglas B Villaret.   

Abstract

BACKGROUND: The authors analyzed the outcomes of patients treated with radiotherapy (RT) alone or combined with surgery for carcinoma of the salivary glands.
METHODS: Between October 1964 and June 2003, 224 previously untreated patients were treated with curative intent with RT alone (n = 64) or combined with surgery (n = 160) at the University of Florida College of Medicine (Gainesville, FL). The median follow-up period was 5.0 years (range, 0.4-31.6 years).
RESULTS: The 10-year local control rate was 75%. Multivariate analysis of local control revealed that T classification (P < 0.0001) and treatment group (P < 0.0001) impacted this end point. Patients treated with surgery and adjuvant RT had improved local control compared with patients treated with RT alone. The 10-year locoregional control rate was 68%. Multivariate analysis of locoregional control revealed that overall stage (P < 0.0001) and treatment group (P = 0.0002) significantly influenced this end point. The 10-year distant metastasis-free survival rate was 68%. Multivariate analysis of distant metastasis-free survival revealed that overall stage (P < 0.0001) significantly influenced this end point. The 10-year cause-specific and overall survival rates were 57% and 44%, respectively. Multivariate analysis of cause-specific survival revealed that overall stage (P < 0.0001) significantly impacted this end point. Twenty-three patients (10%) experienced severe complications.
CONCLUSIONS: A substantial proportion of patients with salivary gland carcinoma were cured with surgery combined with adjuvant RT. RT alone was used for patients with unresectable tumors and cured approximately 20% of those with advanced-stage disease. The probability of cure was influenced by the extent of disease and treatment group. Copyright 2005 American Cancer Society.

Entities:  

Mesh:

Year:  2005        PMID: 15880750     DOI: 10.1002/cncr.21083

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  38 in total

1.  Prognostic factors in patients with high-risk locally advanced salivary gland cancers treated with surgery and postoperative radiotherapy.

Authors:  Trevor M Feinstein; Stephen Y Lai; Diana Lenzner; William Gooding; Robert L Ferris; Jennifer R Grandis; Eugene N Myers; Jonas T Johnson; Dwight E Heron; Athanassios Argiris
Journal:  Head Neck       Date:  2011-01-31       Impact factor: 3.147

2.  Results of surgery plus postoperative radiotherapy for patients with malignant parotid tumor.

Authors:  Shogo Matsuda; Hiroyoshi Iguchi; Takuhito Tada; Masako Hosono; Masahiko Osawa; Yuuko Kuwae; Hideyuki Morimoto; Eiichiro Okazaki; Kosuke Amano; Yoshitaka Miki; Shinichi Tsutsumi; Yasuhiko Shimatani; Yukio Miki
Journal:  Jpn J Radiol       Date:  2015-07-10       Impact factor: 2.374

3.  Outcomes and prognostic factors in modern era management of major salivary gland cancer.

Authors:  Naresh Jegadeesh; Yuan Liu; Roshan S Prabhu; Kelly R Magliocca; David M Marcus; Kristin A Higgins; Jeffrey M Vainshtein; J Trad Wadsworth; Jonathan J Beitler
Journal:  Oral Oncol       Date:  2015-05-29       Impact factor: 5.337

4.  The role of elective neck dissection in high-grade parotid malignancy: A hospital-based cohort study.

Authors:  R Alex Harbison; Alan J Gray; Ted Westling; Marco Carone; Cristina P Rodriguez; Neal D Futran; Richard B Cannon; Jeffrey Houlton
Journal:  Laryngoscope       Date:  2019-08-29       Impact factor: 3.325

5.  Stromal collagen type VI associates with features of malignancy and predicts poor prognosis in salivary gland cancer.

Authors:  Linus Angenendt; Jan-Henrik Mikesch; Dennis Görlich; Alina Busch; Irina Arnhold; Claudia Rudack; Wolfgang Hartmann; Eva Wardelmann; Wolfgang E Berdel; Markus Stenner; Christoph Schliemann; Inga Grünewald
Journal:  Cell Oncol (Dordr)       Date:  2018-06-15       Impact factor: 6.730

6.  Sperm associated antigen 9 (SPAG9) expression and humoral response in benign and malignant salivary gland tumors.

Authors:  Sumit Agarwal; Deepak Parashar; Namita Gupta; Nirmala Jagadish; Alok Thakar; Vaishali Suri; Rajive Kumar; Anju Gupta; Abdul S Ansari; Nirmal Kumar Lohiya; Anil Suri
Journal:  Oncoimmunology       Date:  2014-12-02       Impact factor: 8.110

7.  Retrograde parotidectomy under local anesthesia for benign, malignant, and inflammatory lesions.

Authors:  Michael Chang; Alanna Coughran; Yu-Jin Lee; Jeremy Collins; Davud Sirjani
Journal:  Am J Otolaryngol       Date:  2019-01-14       Impact factor: 1.808

Review 8.  Salivary gland carcinomas.

Authors:  Tobias Ettl; Stephan Schwarz-Furlan; Martin Gosau; Torsten E Reichert
Journal:  Oral Maxillofac Surg       Date:  2012-07-29

9.  Treatment Results of Major Salivary Gland Cancer by Surgery with or without Postoperative Radiation Therapy.

Authors:  Jae Myoung Noh; Yong Chan Ahn; Heerim Nam; Won Park; Chung-Hwan Baek; Young-Ik Son; Han-Sin Jeong
Journal:  Clin Exp Otorhinolaryngol       Date:  2010-06-30       Impact factor: 3.372

10.  Migration of radioactive iodine-125 seeds: case report.

Authors:  Wanfu Zhang; Kaiyuan Luo
Journal:  Indian J Surg       Date:  2012-06-19       Impact factor: 0.656

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.